Department of Health and Human Services, through National Institutes of Health, awarded Vast Therapeutics, Inc. of Morrisville, NC $1,988,594 under the SBIR program (Phase II), with work starting 2024-12-20 and running to 2026-11-30. It is one of 2 SBIR and STTR awards Vast Therapeutics, Inc. received in the last two years, $3,938,723 in all. Each figure links to the federal record.
The award
| Recipient | Vast Therapeutics, Inc. (Morrisville, NC) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $1,988,594 |
| Period of performance starts | 2024-12-20 |
| Period of performance ends | 2026-11-30 |
| Award number | R44AI184225 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Morrisville, Wake County, NC |
| Recipient registry id (UEI) | CYDMYQAP1ZW7 |
Want the whole picture on Vast Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vast Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vast Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Nebulized ALX1 as a treatment for pseudomonas aeruginosa infections in bronchiectasis patients - summary bronchiectasis is characterized by dysregulated inflammation that leads to enlarged airways (bronchi) that are less
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-05-26 | Continuation | 000 | $988,594 |
| 2025-04-11 | Revision | 002 | $0 |
| 2024-12-27 | Revision | 001 | $0 |
| 2024-12-20 | New | 000 | $1,000,000 |
Nebulized ALX1 as a treatment for pseudomonas aeruginosa infections in bronchiectasis patients - summary bronchiectasis is characterized by dysregulated inflammation that leads to enlarged airways (bronchi) that are less able to clear mucus secretions, increasing the levels of bacteria in the lungs and chronic inflammation. This vicious cycle leads to breakdown of the airways and permanent lung damage; recurring respiratory infections in bronchiectasis cause significant morbidity and mortality. Pseudomonas aeruginosa infections are particularly deleterious with a 30-50% 5-YEAR mortality rate in these patients. In addition to the multi-drug resistance mechanisms in this pathogen, airway mucus and the biofilm matrix both frustrate the immune response and mitigate the effectiveness of antibiotics. Repeated, intermittent use of unsuccessful antibiotic regimens lead to antimicrobial resistance (amr), further reducing treatment options. New antimicrobial therapies to effectively treat bacterial lung infections without promoting amr are greatly needed. Nitric oxide (no) is an endogenous broad-spectrum antibacterial agent produced by the immune system (e.g., macrophages and neutrophils) to battle pathogens. In certain diseases, the levels of naturally produced no are often inadequate to successfully fight infections. The inhalation of no-releasing prodrugs provides a means for deliveri ...
From the federal award record.
Other SBIR and STTR awards to Vast Therapeutics, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-09-11 | Department of Health and Human Services | SBIR Phase II | $1,950,129 | Nebulized ALX1 as a treatment for difficult non-tuberculous mycobacterial lung infections (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Vast Therapeutics, Inc.Look up Vast Therapeutics, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.